Summit Financial Wealth Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$240K Hold
22,143
0.03% 193
2026
Q1
$246K Hold
22,143
0.03% 170
2025
Q4
$367K Hold
22,143
0.05% 134
2025
Q3
$272K Hold
22,143
0.04% 148
2025
Q2
$212K Sell
22,143
-9,000
-29% -$49.8K 0.04% 161
2025
Q1
$195K Sell
31,143
-36,982
-54% -$225K 0.04% 148
2024
Q4
$384K Buy
68,125
+39,093
+135% +$484K 0.08% 105
2024
Q3
$525K Buy
+29,032
New +$406K 0.1% 84

Other funds holding PHAT

Summit Financial Wealth Advisors's PHAT Position: Q2 2026 in Review

Summit Financial Wealth Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 22,143 shares worth $240K. The position accounts for 0.03% of the portfolio, ranked #193.

Summit Financial Wealth Advisors first reported a position in PHAT in Q3 2024 and has held it in 8 quarters since. The position peaked at $525K in Q3 2024. 16 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Summit Financial Wealth Advisors held 22,143 shares of Phathom Pharmaceuticals worth $240K as of Q2 2026.
  • Summit Financial Wealth Advisors left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 0.03% of Summit Financial Wealth Advisors's portfolio in Q2 2026, its #193 holding.
  • Summit Financial Wealth Advisors first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Summit Financial Wealth Advisors's Phathom Pharmaceuticals position peaked at $525K in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Summit Financial Wealth Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.